GSK:NYSE
GSK plc
$46.50
arrow_downward
-0.05%(-0.025) 1D
$46.50
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:03 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
$46.61
High
$46.82
Low
$46.26
Mkt. cap
92.67B
Avg. vol.
3.71M
Volume
8.54M
Dividend
3.91%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
14.90
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.12
Beta
0.25
Shares outstanding
2.16B
No. of employees
67K
Open
$46.61
High
$46.82
Low
$46.26
Mkt. cap
92.67B
Avg. vol.
3.71M
Volume
8.54M
Dividend
3.91%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
14.90
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.12
Beta
0.25
Shares outstanding
2.16B
No. of employees
67K
News stories
From web sources and news partners
The Mercury
·
55 minutes ago
GSK investing $800 million to expand in Montgomery County
WFMZ.com
·
3 hours ago
Gov. Shapiro secures over $800M investment from GSK to expand operations, creating over 300 new jobs
marketscreener.com
·
4 hours ago
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs
Seeking Alpha
·
4 hours ago
GSK to expand Pennsylvania presence with over $800M investment
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com